Nektar Therapeutics
In the published model solve dated 2026-Q2, anchored at $73.02, Nektar Therapeutics (NKTR) is priced for today's economics sustained for ~29.4 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 27, 2026 from SEC EDGAR filings.
• Nektar is a clinical-stage biotech whose value rests almost entirely on one drug, rezpegaldesleukin, which recently met its primary and key secondary endpoints in a Phase 2b study in moderate-to-severe atopic dermatitis. [Source: Nektar REZOLVE-AD topline results] • The defining risk is the long road to revenue: pivotal Phase 3 trials are only now beginning, with initial data expected in 2028 and a regulatory submission targeted for 2029, so the company faces years of spending before any produ
Is NKTR overvalued? See what's priced in →
207 institutional managers reported holding NKTR in 13F filings for the quarter ended 2026-03-31. 64 opened new positions that quarter. Held by FMR (Fidelity), Vanguard Group, Two Sigma, among others. On the short side, 4.9M shares were sold short as of the 2026-06-15 count, about 20% of shares outstanding (4.9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
NKTR's share count grew 103.1% over the past five years even with $3.00M spent on repurchases. It pays no dividend. Cash returned over the past three years: $3.00M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at NKTR over the trailing three years. Absence is a fact about the company, not a signal. 3 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
NKTR's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-10 | -10.7% | -50.3% |
| 2023-11-09 | -5.7% | +13.8% |
| 2024-03-06 | +13.3% | +80.2% |
| 2024-05-11 | +7.3% | -19.3% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
NKTR's latest 8-K filings: 2026-06-05 (items 5.07); 2026-05-08 (items 1.01, 5.02, 9.01); 2026-05-07 (items 2.02, 9.01); 2026-04-23 (items 1.01, 8.01, 9.01); 2026-04-20 (items 7.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.